PDS Biotech reports Q3 net loss $10.7M; modifies Phase 3 trial design to cut costs

PDS Biotechnology Corp

2024-Q3 EPS reported -$0.82

Net loss of $10.7M ($0.29/share) vs $10.8M ($0.35/share) in Q3 2023; operating expenses declined slightly.
Cash and equivalents $49.8M as of Sept 30, 2024; cash runway supports VERSATILE-003 launch.
Phase 3 VERSATILE-003 trial design modified: ~350 patients, 2:1 randomization, overall survival primary endpoint.
Amended IND submitted Nov 2024; FDA clearance expected by mid-Dec; site activation targeted Q1 2025.
R&D expenses $6.8M (+$0.4M YoY) on higher manufacturing; G&A $3.4M (-$0.7M YoY) on lower personnel costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.